Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus

Letters3 July 2012Oral Pharmacologic Treatment of Type 2 Diabetes MellitusAmir Qaseem, MD, PhD, MHA, Linda Humphrey, MD, MPH, and Paul Shekelle, MD, PhDAmir Qaseem, MD, PhD, MHAFrom American College of Physicians, Philadelphia, PA 19106; Oregon Health and Science University, Portland, OR 97201; and West Los Angeles Veterans Affairs Medical Center, Los Angeles, CA 90073.Search for more papers by this author, Linda Humphrey, MD, MPHFrom American College of Physicians, Philadelphia, PA 19106; Oregon Health and Science University, Portland, OR 97201; and West Los Angeles Veterans Affairs Medical Center, Los Angeles, CA 90073.Search for more papers by this author, and Paul Shekelle, MD, PhDFrom American College of Physicians, Philadelphia, PA 19106; Oregon Health and Science University, Portland, OR 97201; and West Los Angeles Veterans Affairs Medical Center, Los Angeles, CA 90073.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-1-201207030-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Dr. Moskowitz, Drs. Rodbard and Jellinger, and Dr. Richard and colleagues for their comments regarding the recent clinical guideline on oral pharmacologic treatment of type 2 diabetes mellitus.In response to Dr. Moskowitz, on the basis of the available evidence, we believe that it was important to mention that metformin is contraindicated for patients with such conditions as renal impairment and heart failure. Most current clinical guidelines identify very specific contraindications to the use of metformin. We disagree that metformin is harmless in all patients except those with severe renal impairment because the precise creatinine threshold ...References1. Qaseem A, Forland F, Macbeth F, Ollenschläger G, Phillips S, van der Wees P; Board of Trustees of the Guidelines International Network. Guidelines international network: toward international standards for clinical practice guidelines. Ann Intern Med. 2012;156:525-31. [PMID: 22473437] LinkGoogle Scholar2. Institute of Medicine. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Pr; 2011. Google Scholar3. Bennett WL, Wilson L, Bolen S, Maruthur NM, Singh S, Chatterjee R, et al. Oral Diabetes Medications for Adults with Type 2 Diabetes: An Update. Rockville, MD: Agency for Healthcare Research and Quality; 2011. Accessed at www.effectivehealthcare.ahrq.gov/ehc/products/155/644/CER27_OralDiabetesMeds_20110623.pdf on 3 April 2012. Google Scholar Author, Article, and Disclosure InformationAffiliations: From American College of Physicians, Philadelphia, PA 19106; Oregon Health and Science University, Portland, OR 97201; and West Los Angeles Veterans Affairs Medical Center, Los Angeles, CA 90073.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-2857. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians Amir Qaseem , Linda L. Humphrey , Donna E. Sweet , Melissa Starkey , Paul Shekelle , and Metrics Cited byAnalysis of Metformin and Five Gliptins in Counterfeit Herbal Products: Designs of Experiment Screening and OptimizationChlorogenic Acid and Rutin Play a Major Role in the In Vivo Anti-Diabetic Activity of Morus alba Leaf Extract on Type II Diabetic Rats 3 July 2012Volume 157, Issue 1Page: 76-77KeywordsAlgorithmsHbA1cHeart failureLactic acidosisSafetySystematic reviewsTreatment guidelinesType 2 diabetes ePublished: 3 July 2012 Issue Published: 3 July 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...